American Society of Hirudotherapy

Anticoagulation Strategies in Pediatric Cardiopulmonary Bypass, Weight-Based vs. Concentration-Based Approaches

Literature review published in The journal of extra-corporeal technology (2022)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureHarnish et al. · The journal of extra-corporeal technology, 2022

Abstract

Pediatric patients undergoing cardiopulmonary bypass (CPB) require adequate anticoagulation to combat hemostatic activation. Heparin is used to bind and catalyze antithrombin III (ATIII) that works to inhibit clot formation. To dose heparin, a weight-based (WB) or patient-specific concentration-based (PSCB) method can be used. The WB protocol calculates the dose based on the patients' weight and uses an activated clotting time (ACT) test to ensure anticoagulation. The ACT has limitations during CPB especially for pediatric patients who have immature hemostatic systems. The PSCB method predicts the patients' response to heparin by projecting a heparin dose-response (HDR) curve. Some investigators have found benefit to using the PSCB method but further investigation into how well the HDR predicts the heparin response is needed. A literature review was conducted for studies that looked at heparin management strategies in pediatric CPB patients between 1992 and 2020. Articles that focused on pediatric physiology, heparin management strategies, and anticoagulation were included. Articles older than 1990 were excluded. The literature review highlights that utilizing the PSCB approach more adequately anticoagulated patients. The WB protocol was found to have several flaws due to its reliance on the ACT, especially in infants. The results show that further investigation is needed to understand why there is benefit to using the PSCB approach. Observing the association between the HDR curve and subsequent heparin concentrations could determine how accurately it predicts the patients' response to heparin and why there is benefit to using this method.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood CoagulationCardiopulmonary BypassChildHemostaticsHeparinHumansInfantWhole Blood Coagulation Time

Summary

This literature review of heparin management in pediatric cardiopulmonary bypass compares weight-based dosing using activated clotting time with patient-specific concentration-based dosing, finding the latter achieved more adequate anticoagulation, especially where ACT has flaws in infants.

Why This Matters for Hirudotherapy

This literature review compares weight-based versus patient-specific concentration-based heparin dosing in pediatric cardiopulmonary bypass, concluding that the concentration-based approach more adequately anticoagulated patients while noting the limitations of activated clotting time testing in infants and calling for further study. Its connection to hirudotherapy is indirect: it documents the practical difficulty and patient-specific variability of heparin anticoagulation, which underpins the broader interest in alternative anticoagulant mechanisms such as the leech-derived direct thrombin inhibitor hirudin. The caveat is that this review concerns systemic heparin dosing in a surgical-bypass setting and makes no reference to leeches or hirudotherapy, so it is context only and offers no evidence for leech therapy.

Citation

Reference (Vancouver style)

Harnish J, Beyer K, Collins J. Anticoagulation Strategies in Pediatric Cardiopulmonary Bypass, Weight-Based vs. Concentration-Based Approaches. J Extra Corpor Technol. 2022;54(2):153-160. doi:10.1182/ject-153-160. PMID: 35928334

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.